Clinical trials: Neoplasms, Metastatic
Metastatic Breast Cancer, Oligoprogression
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
Recent advances in systemic therapy have facilitated improved progression-free survival (PFS) and treatment tolerability in metastatic breast cancer patients (MBC).
- Trial name
- STAR-B (NCT06489821)
- Testing
- Stereotactic body radiotherapy
- Volunteers
- 36 people
- Sponsor
- Juravinski Cancer Center
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Metastatic Solid Tumors.
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR.
- Trial name
- NCT00159016
- Testing
- Glivec
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Hadassah Medical Organization
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
ARID1A and/or KDM6A Mutation and CXCL13 Expression
This phase II trial studies the effect of nivolumab in urothelial cancer that has spread to other places in the body (metastatic), specifically in patients with aberrations in ARID1A gene (ARID1A mutation) and correlate with…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT04953104
- Testing
- Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Metastatic Colorectal Cancer
OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
- Trial name
- VELVET (NCT01802684)
- Testing
- aflibercept
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or…
- Trial name
- NCT00004009
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Stage IV Breast Cancer
Oxaliplatin in Treating Patients With Metastatic Breast Cancer
This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer.
- Trial name
- NCT02077998
- Testing
- carbon C 14 oxaliplatin, oxaliplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Davis
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
Non Small Cell Lung Cancer
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small…
- Trial name
- NCT03425006
- Testing
- Itacitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Metastatic Melanoma
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo.
- Trial name
- NCT00724841
- Testing
- Obatoclax Mesylate, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gemin X
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Breast Cancer
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
This phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative…
- Trial name
- NCT06042894
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor
- Trial name
- NCT03493945
- Testing
- M7824, N-803, MVA-BN-Brachyury
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
This is the first-in-human trial with BYON3521, an antibody-drug conjugate (ADC) comprising a humanized IgG1 monoclonal antibody directed against the c-MET receptor covalently conjugated to a duocarmycin-containing linker-drug.
- Trial name
- NCT05323045
- Testing
- BYON3521
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Upper Extremity Deep Vein Thrombosis, Secondary
The Side of Implantable Central Vascular Catheters and Complications
Whether the side of implantable CVCs was associated with the complication rates remains unclear. The investigators plan this study to explore this issue by randomizing patients to receive CVC implantation at the left subclavian…
- Trial name
- NCT01525277
- Where
- Taiwan
- Volunteers
- 246 people
- Sponsor
- National Taiwan University Hospital
Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.
- Trial name
- ePPS (NCT06211257)
- Testing
- Dematerialized Personalized Care Plan (ePCP)
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.